We could not find any results for:
Make sure your spelling is correct or try broadening your search.
New York, NY, April 23, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by...
New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB, VCXB.U, VCXB WS) (“10X III”), announced today that NYSE Regulation (“NYSER”), by...
NEW YORK, NY (United States), Jan. 08, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (“10X III”) (NYSE American:VCXB), a publicly traded special purpose acquisition...
New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by...
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) (“10X III”) today announced that it is transferring the listing of its...
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing...
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.99 | -8.32632464256 | 11.89 | 11.89 | 10.81 | 975 | 10.9 | CS |
4 | 0.14 | 1.30111524164 | 10.76 | 11.99 | 10.76 | 185 | 10.98625068 | CS |
12 | 0.61 | 5.92808551992 | 10.29 | 12.1 | 9.82 | 192 | 10.96325428 | CS |
26 | 0.12 | 1.11317254174 | 10.78 | 13 | 9.66 | 258 | 10.84673083 | CS |
52 | 0.29 | 2.73327049953 | 10.61 | 13 | 9.5 | 242 | 10.85050513 | CS |
156 | 0.29 | 2.73327049953 | 10.61 | 13 | 9.5 | 242 | 10.85050513 | CS |
260 | 0.29 | 2.73327049953 | 10.61 | 13 | 9.5 | 242 | 10.85050513 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions